SeQuent receives CEP approval for Diclazuril API

Sequent announced that it has received 'Certificate of Suitability' (CEP) for its generic active pharmaceutical ingredient (API) Diclazuril in the EU.

Diclazuril is an antiprotozoal drug and is a preferred drug of choice for treating coccidiosis in livestock due to zero-day withdrawal period. It is also used in horses to treat equine protozoal myeloencephalitis caused by Sarcocystis neurona.

Sequent/Alivira is the second company in the world to receive approval for Diclazuril from the European Directorate for the Quality of Medicines (EDQM). The product was also recently commercialised in the US with supplies to the innovator.

This is Alivira's 11th CEP approval from the EDQM. Further, the company also has 21 filings for veterinary APIs in the US, making it the largest portfolio for the regulated markets in the animal health Industry.

Diclazuril is manufactured at Alivira's Vizag facility, the only US FDA approved veterinary API site in India.

Shares of SEQUENT SCIENTIFIC LTD. was last trading in BSE at Rs.211.7 as compared to the previous close of Rs. 215.95. The total number of shares traded during the day was 35719 in over 1018 trades.

The stock hit an intraday high of Rs. 216.95 and intraday low of 207.05. The net turnover during the day was Rs. 7572105.

Source : Equity Bulls

Keywords